Valneva (VALN) Stock Price, News & Analysis

Company Overview

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli. These vaccines are distributed across Europe, North America, Canada and select emerging markets through a network of subsidiaries and distribution partners. Valneva’s product portfolio also includes earlier-stage candidates targeting Lyme disease, chikungunya and other vector-borne diseases, as well as a vaccine program against COVID-19.

The company was formed in 2013 through the merger of Austrian-based Intercell AG and French biotech Vivalis SA, combining expertise in vaccine research and manufacturing. Valneva is dual-listed on Euronext Paris and the Nasdaq Stock Market, reflecting its ambition to serve both European and U.S. public health markets. Its manufacturing facilities are located in Scotland, Sweden, Austria and the United States, supporting both clinical and commercial vaccine supply.

Valneva is led by Chief Executive Officer Thomas Lingelbach, whose background in biopharmaceutical development guides the company’s strategic priorities. Under his leadership, Valneva continues to expand its pipeline, strengthen global partnerships and invest in capacity to respond to future infectious disease challenges.

Key Stats

• Today's Range: $8.77 to $9.11
• 50-Day Range: $5.67 to $12.14
• 52-Week Range: $3.62 to $12.25
• Volume: 130,301 shs
• Average Volume: 150,390 shs
• Market Capitalization: $746.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.33
• Consensus Rating: Buy

Valneva Stock Analysis - MarketRank™

Valneva scored higher than 40% of companies evaluated by MarketBeat, and ranked 732nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Valneva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Valneva has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Valneva are expected to decrease in the coming year, from $0.13 to ($0.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Valneva is -8.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Valneva is -8.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Valneva has a P/B Ratio of 3.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.09% of the float of Valneva has been sold short.

Short Interest Ratio / Days to Cover

Valneva has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Valneva has recently increased by 64.62%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Valneva does not currently pay a dividend.

Dividend Growth

Valneva does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.09% of the float of Valneva has been sold short.

Short Interest Ratio / Days to Cover

Valneva has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Valneva has recently increased by 64.62%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.32

News Sentiment

Valneva has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Valneva this week, compared to 5 articles on an average week.

Search Interest

3 people have searched for VALN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Valneva insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.91% of the stock of Valneva is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 11.39% of the stock of Valneva is held by institutions.

VALN Stock Analysis - Frequently Asked Questions

How have VALN shares performed this year?

Valneva's stock was trading at $4.37 at the beginning of 2025. Since then, VALN shares have increased by 100.7% and is now trading at $8.77.

How were Valneva's earnings last quarter?

Valneva SE Sponsored ADR (NASDAQ:VALN) announced its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.11. The company had revenue of $54.84 million for the quarter, compared to analyst estimates of $46.28 million. Valneva had a negative net margin of 33.87% and a negative trailing twelve-month return on equity of 34.78%.
Read the conference call transcript.

When did Valneva IPO?

Valneva (VALN) raised $99 million in an initial public offering on Thursday, May 6th 2021. The company issued 3,500,000 shares at a price of $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. served as the underwriters for the IPO.

Who are Valneva's major shareholders?

Top institutional investors of Valneva include Frazier Life Sciences Management L.P. (1.71%) and Marex Group plc (0.01%).

How do I buy shares of Valneva?

Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Valneva own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Valneva investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/04/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VALN
• CIK: 1836564
• Web: valneva.com
• Phone: 33-2-28-07-37-10
• Fax: N/A
• Employees: 700
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Valneva: $15.33
• High Price Target: $18.00
• Low Price Target: $14.00
• Potential Upside/Downside: +74.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 67.46
• P/E Growth: N/A
• Net Income: -$13.25 million
• Net Margins: -33.87%
• Pretax Margin: -6.77%
• Return on Equity: -34.78%
• Return on Assets: -13.43%

Debt

• Debt-to-Equity Ratio: 0.66
• Current Ratio: 2.27
• Quick Ratio: 1.77

Sales & Book Value

• Annual Sales: $183.52 million
• Price / Sales: 4.07
• Cash Flow: $0.10 per share
• Price / Cash Flow: 90.57
• Book Value: $2.49 per share
• Price / Book: 3.52

Miscellaneous

• Outstanding Shares: 85,090,000
• Free Float: 72,406,000
• Market Cap: $746.24 million
• Optionable: Not Optionable
• Beta: 1.79